Literature DB >> 2960710

Antidepressants in panic disorder and agoraphobia.

R B Lydiard1, J C Ballenger.   

Abstract

A survey of the literature on the use of antidepressants for treating patients with panic disorder and agoraphobia with panic attacks suggests that both tricyclic antidepressants and monoamine oxidase inhibitors have efficacy in blocking panic attacks. While we have witnessed dramatic progress in the pharmacological treatment of panic-related disorders over the past 20 years, many unresolved questions remain. Further understanding of dose-response relationships, optimal duration of treatment and predictors of relapse are needed to optimize pharmacological treatment of panic-related disorders. Studies comparing the relative efficacy and side effects spectrum of various effective medications are needed. It is not presently possible to specify which patients will require medication or behavioral treatment alone, and studies to date have incompletely examined this murky issue. Further prospective studies directly comparing the pharmacological and behavioral treatments will help further elucidate the relative contribution of each treatment and possibly clarify which patients require both treatments. Controlled studies in the future which standardize dosage and duration of treatment and use comparable, objective outcome variables promise to provide important theoretical and clinical information regarding the pharmacological treatment of panic-related disorders.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 2960710     DOI: 10.1016/0165-0327(87)90020-6

Source DB:  PubMed          Journal:  J Affect Disord        ISSN: 0165-0327            Impact factor:   4.839


  11 in total

1.  Self- and observer assessment in anxiolytic drug trials: a comparison of their validity.

Authors:  W Maier; M Albus; R Buller; D Nutzinger; D Shera; P Bech
Journal:  Eur Arch Psychiatry Clin Neurosci       Date:  1990       Impact factor: 5.270

2.  Treating panic.

Authors:  P Tyrer
Journal:  BMJ       Date:  1989-01-28

3.  Experimental anxiety and antidepressant drugs: the effects of moclobemide, a selective reversible MAO-A inhibitor, fluoxetine and imipramine in mice.

Authors:  L de Angelis
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1996 Aug-Sep       Impact factor: 3.000

4.  The effects of repeated doses of clomipramine and alprazolam on physiological, psychomotor and cognitive functions in normal subjects.

Authors:  D Allen; H V Curran; M Lader
Journal:  Eur J Clin Pharmacol       Date:  1991       Impact factor: 2.953

5.  Effects of fluoxetine and buspirone on the panicolytic-like response induced by the activation of 5-HT1A and 5-HT2A receptors in the rat dorsal periaqueductal gray.

Authors:  Valquíria Camin de Bortoli; Regina Lúcia Nogueira; Hélio Zangrossi
Journal:  Psychopharmacology (Berl)       Date:  2005-10-29       Impact factor: 4.530

6.  Monoamine oxidase inhibitors: clinical review.

Authors:  R A Remick; C Froese
Journal:  Can Fam Physician       Date:  1990-06       Impact factor: 3.275

Review 7.  Overview of panic disorder.

Authors:  J C Ballenger
Journal:  Trans Am Clin Climatol Assoc       Date:  1994

Review 8.  A risk-benefit assessment of buspirone in the treatment of anxiety disorders.

Authors:  J C Pecknold
Journal:  Drug Saf       Date:  1997-02       Impact factor: 5.606

9.  Effects of acute and chronic anti-panic drug administration on conflict behavior in the rat.

Authors:  D J Fontana; T J Carbary; R L Commissaris
Journal:  Psychopharmacology (Berl)       Date:  1989       Impact factor: 4.530

Review 10.  Anxiety disorders in family practice. Diagnosis and management.

Authors:  W W Rosser; M Borins; D Audet
Journal:  Can Fam Physician       Date:  1994-01       Impact factor: 3.275

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.